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The Fusarium species are major fungal contaminants of maize, that produce an extremely toxic 
mycotoxin called Fumonisin B1 (FB1). Fumonisin B1 is a known causative agent of animal-related 
mycotoxicosis and is implicated in cancer initiation in humans (epidemiological) and animals 
(experimental). The mechanisms of tumorigenesis have implicated oxidative stress, incomplete 
apoptosis, and chromatin instability as major contributing factors. While the canonical 
mechanism of FB1 induced ceramide dysregulation and oxidative stress are the established drivers 
of cancer initiation, accumulating evidence indicates that changes in cholesterol metabolism may 
further enhance the tumorigenic potential of FB1. The cholesterolemic effect of FB1 has been 
shown in experimental models yet molecular evidence elucidating the disturbed cholesterol flux 
remains vague. This study investigates the molecular mechanism that regulate the effect of FB1 
on cholesterol homeostasis, by investigating the role of cholesterol flux proteins and their 
regulation at the transcriptional and post translational level, in galactose supplemented HepG2 
liver cells. 
Cancer cells like the liver derived HepG2 cell line, differ from normal tissues with respect to their 
excessive use of aerobic glycolysis, to satisfy the high energy demand. The proven method of 
circumventing the Crabtree effect exhibited by cancer cells, is to replace glucose with galactose 
in the culture media, forcing cells to activate the mitochondria and rely on oxidative 
phosphorylation rather than glycolysis for ATP.  
SIRT1 is a NAD-dependent deacetylase, that responds to changes in nutrient availability, to 
induce regulatory effects on cellular metabolism. The toxicity of FB1 was determined (6hr 
incubation; IC50 = 25µM) on metabolic output, cholesterol regulatory transcription factors and 
key cholesterol flux proteins using the spectrophotometric MTT assay, ATP luciferase assay, 
qPCR (SIRT1, SREBP-1C, LXR, LDLR, PCSK9 and ABCA1) and western blots (SIRT1, SREBP-
1C, LXR, LDLR, PCSK9 and ABCA1).  
FB1 induced differential HepG2 cell viability and metabolic output. There was no effect on cell 
viability for the glucose-supplemented media, while a decrease in cell viability was observed for 
the galactose-supplement media. Concurrent with the decrease in cell viability of the galactose-
supplementation, a decrease in HepG2 ATP output was observed (p=0.0135). FB1 did not 
compromise membrane integrity, despite the decrease in cell viability. The expression of the 
SIRT1 gene (p=0.0004) and protein (p=0.0005) was significantly increased by FB1. The 
expression of the SREBP-1c gene (p=0.0050) was increased while protein expression (p=0.0063) 
was decreased. The role of LXR and PCSK9 in the regulation of LDLR was further highlighted. 
xv 
 
FB1 increased the expressions of LXR (p=0.0003) and LDLR (p=0.0004 and p=0.0049 
respectively) genes and proteins but decreased the gene (p=0.0017) and protein (p=0.0018) 
expression of PCSK9.  
The data provides evidence that SIRT1 reduces the expression of PCSK9 and deacetylates LXR 
to prevent degradation of LDLR, resulting in dysregulated cholesterol flux in liver cells. The 
disruption of cholesterol homeostasis by FB1 is beginning to shift away from established ceramide 
synthase inhibition, changing the perspective to shed light on the diseases caused by dysregulated 




CHAPTER 1: INTRODUCTION 
Mycotoxins are fungal secondary metabolites that adversely affect humans, animals and plants 
and their contamination of foods and animal feeds presents a significant problem to food security 
(Cardwell, Desjardins et al. 2001, Bhat and Vasanthi 2003). Fumonisin B1 (FB1) is a group 2B 
carcinogenic mycotoxin,  mainly produced by Fusarium verticilliodies and Fusarium 
proliferatum which commonly infect maize and other agricultural products including rice, 
sorghum, wheat bran and soybean meal (Stockmann-Juvala and Savolainen 2008, Zain 2011). 
FB1 predominates in 70% of the total FBs naturally occurring in infected food and feed samples 
(Kamle, Mahato et al. 2019). Thus, it comes as no surprise that Fumonisins have been associated 
with elevated human oesophageal cancer in Africa, America and Asia (Zain 2011, Alizadeh, 
Rohandel et al. 2012, Xue, Tang et al. 2019). A study showed a correlation between the 
consumption of Fumonisin contaminated maize, and human oesophageal cancer in South Africa 
(Marasas, Riley et al. 2004). The outcomes of FB1-induced toxicity includes; oxidative stress, 
cytotoxicity, apoptosis, immunotoxic effects and epigenetic dysregulation (Stockmann-Juvala 
and Savolainen 2008). The canonical mechanism of FB1 toxicity is based on its structural 
similarity to cellular sphingolipids and subsequent competitive inhibition of the enzyme ceramide 
synthase resulting in an accumulation of sphingosine, sphinganine and its derivatives (Merrill, 
Van Echten et al. 1993, Soriano, Gonzalez et al. 2005, Zitomer, Mitchell et al. 2009). 
A major portion of ingested FB1 is distributed to the liver, and focus has been on FB1 induced 
hepatotoxicity and liver cancer. FB1-mediated tumorigenesis has been attributed to chromatin 
instability, via FB1 induced hypomethylation of global DNA (Chuturgoon, Phulukdaree et al. 
2014) and induced oxidative stress in HepG2 cells (Gelderblom, Abel et al. 2001, Arumugam, 
Pillay et al. 2019). 
Interestingly, FB1 has complex activity on cholesterol metabolism. In the liver and plasma in vivo, 
FB1 increases cholesterol levels, while in vitro studies have shown a decrease in free cholesterol 
(Gelderblom, Smuts et al. 1996, Gelderblom, Smuts et al. 1997) . In normal conditions, the liver 
is the primary site for cholesterol biosynthesis, storage, and also the site of cholesterol excretion 
and metabolism (Nemes, Åberg et al. 2016). Cancer cells exhibit lipid and cholesterol reliance, 
which is met by increasing the uptake of dietary lipids and lipoproteins or via over activation of  
lipogenesis and cholesterol synthesis, a feature considered to be a hallmark of cancer progression 
(Beloribi-Djefaflia, Vasseur et al. 2016). Cholesterol is a major membrane component, that offers 
stability, however cholesterol also functions in the cytoplasm, where it is stored in lipid droplets, 
which from the main lipid stores in eukaryotes (Maxfield and Wüstner 2002, Martin and Parton 
2006). Recent studies have highlighted the possibility of liposomal cholesterol activating 
mammalian target of rapamycin complex 1 (mTORC1) via the SLC38A9-Neimann-Pick C1 
signalling complex (Castellano, Thelen et al. 2017). The activation of mTORC1 increases cell 
proliferation, invasion and metastasis of cancer cells (Kim, Cook et al. 2017). Despite being a 
major component for membrane integrity, cholesterol is also a component of lipid rafts, whose 
structure and function are dependent on the composition of cholesterol and phospholipids (Yan, 
Qu et al. 2014). Lipid rafts facilitate signal transduction of oncogenic signals, thus alterations in 
cholesterol level may impair the integrity of lipid rafts, leading to detrimental outcomes (George 
and Wu 2012). 
The low-density lipoprotein receptor (LDLR) pathway is a negative feedback system, that plays 
a key role in the regulation of plasma and intracellular cholesterol homeostasis. The LDLR is a 
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transmembrane protein, responsible for cellular lipid uptake, and cholesterol transfer (Zhang, Ma 
et al. 2016). Mature LDLR presents on the cell surface where it mediates the internalisation and 
degradation of plasma LDL-cholesterol (Zhang, Ma et al. 2016). The expression of LDLR is 
tightly regulated both transcriptionally, post-transcriptionally and post-translationally. 
Proprotein convertase subtilisin kexin 9 (PCSK9) is also a key player in cholesterol metabolism, 
due to its regulatory role on LDLR (Peterson, Fong et al. 2008). The PCSK9 binds to LDLR on 
the cell membrane, internalises it, and then directs LDLR to the lysosome for degradation (Zhang, 
Ma et al. 2016). In this way, PCSK9 exhibits posttranslational regulation of LDLR. Proprotein 
convertase subtilisin kexin 9 itself, is also subject to regulation. In vivo and in vitro activation of 
Sirtuin 1 (SIRT1), lowered plasma PCSK9 secretion in murine hepatocytes and mice (Miranda, 
van Tits et al. 2014).   
Sirtuin 1 is a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, that influences 
glucose and lipid metabolism. It has been demonstrated that SIRT1 regulates proteins and genes 
involved in lipid metabolism. To inhibit lipid synthesis and fat storage, SIRT1 down-regulates 
both sterol regulatory element-binding protein-1 (SREBP-1) and SREBP-2 (Ye, Li et al. 2017). 
Sirtuin 1 is also a positive regulator of liver X receptor (LXR). The liver X receptors are key 
transcriptional regulators pf cholesterol metabolism. LXRα and LXRβ are sterol-dependent 
nuclear receptors which are activated in response to excess cellular cholesterol (Zelcer and 
Tontonoz 2006). 
SIRT1 deacetylates LXR, resulting in cholesterol efflux from cells (Ye, Li et al. 2017). It has been 
demonstrated that LXR decreases LDLR-dependent cholesterol uptake via LXR-IDOL (inducible 
degrader of the LDLR) pathway (Zelcer, Hong et al. 2009). Liver X receptor is responsible for 
inducing IDOL, which then catalyses the ubiquitination of LDLR, tagging it degradation (Zelcer, 
Hong et al. 2009). 
The effect of FB1 on cholesterol flux is vague, while its mechanisms of tumorigenesis and the 
canonical action on ceramide are well studied. In this study, to gain a better understanding of FB1 
on cholesterol homeostasis, the change in expression profiles of proteins involved in cholesterol 
transport, were investigated in hepatocellular carcinoma (HepG2) cells supplemented with 
galactose media. The phenomenon described as the Crabtree effect, demonstrates how cancer 
cells rely on aerobic glycolysis, while still retaining the function of oxidative phosphorylation 
(Zheng 2012). A proven intervention of circumventing this phenomenon is to replace glucose 
with galactose in the cell culture media, as demonstrated in several studies (Aguer, Gambarotta 
et al. 2011, Shiratori, Furuichi et al. 2019, Orlicka-Płocka, Gurda-Wozna et al. 2020). 
1.1 Aim: 
To investigate the effect of FB1 on SIRT1, LXR and SREBP-1c and associated proteins in 
cholesterol flux, in oxidatively poised liver HepG2 cells. 
1.2. Hypothesis: 





To determine the following parameters induced by FB1 in HepG2 cells supplemented with 
galactose media: 
Metabolic changes  
Cell membrane integrity 
Expression profiles of key proteins involved in cholesterol flux using western blots. 
Expression of SIRT1, transcription factors; LXR and SREBP1 and their targets; LDLR, PCSK9 




























CHAPTER 2: LITERATURE REVIEW 
2.1 Mycotoxins 
2.1.1 A brief history  
The availability of safe and edible food is crucial for sustaining human and animal life. Food 
shortages are concerning, thus grew the need to store and preserve food for extended periods of 
time. With this came the need for specialized packaging for storage and transport. These factors 
increased the susceptibility of food sources to adverse weather conditions and the exposure to 
different microorganisms. This leads to food spoilage and contamination with different 
microorganisms, including fungi and the mycotoxins they produce (Ahmed Adam, Tabana et al. 
2017). The 1960s outbreak of the Turkey X disease, initiated concern over mycotoxins, where 
approximately 100 000 turkey poults died after consuming aflatoxin contaminated peanut meal 
(Peraica, Radić et al. 1999, Bennett and Klich 2003). This led to the discovery of a large number 
of mycotoxins, from a wide array of fungal genera, which are implicated in several outbreaks and 
disease (Peraica, Radić et al. 1999, Ahmed Adam, Tabana et al. 2017). 
2.1.2 Where do they come from and what do they do? 
The most common producers of mycotoxins are the fungal genera Aspergillus, Penicillium and 
Fusarium (Yiannikouris and Jouany 2002). For growth and metabolism, fungal species absorb 
nutrients of low molecular weights, and as a result of enzymatic degradation of macromolecules, 
produce secondary metabolites known as mycotoxins (Moss 1991). These secondary metabolites 
are not directly required for growth of the fungal species (Fox and Howlett 2008) however, they 
are associated with providing security and protecting the fungus against viral, protozoan and 
bacterial infections (Zain, Awaad et al. 2014). The term mycotoxin is used to describe 
pharmacologically active fungal secondary metabolites, characterized as vertebrate toxicity 
(Bennett and Klich 2003), that are known to cause chronic and acute effects in humans and 
animals.  
Mycotoxins are extensively produced in cereal grains and animal feed during and after harvests 
(Yiannikouris and Jouany 2002). Ecological conditions with high temperatures, heightened 
humidity and rainfall, such as tropical climates, provide favourable conditions for mycotoxin 
formation (Bhat and Vasanthi 2003). Therefore, the severity of contamination is dependent on 
environmental factors and storage practices (Coulombe Jr 1993). The contamination of food and 
feeds with mycotoxins is of global concern, as the ingestion of mycotoxins leads to toxicity (Zain 
2011). Aflatoxin, ochratoxins, trichothecenes and Fumonisin, are some of the major food 
contaminant mycotoxins, which exhibit nephrotoxicity, hepatotoxicity and carcinogenicity in 
humans and animals (Bennett and Klich 2003). Diseases as a result of fungal-derived toxins in 
human and animals has risen extensively (Enyiukwu, Ononuju et al. 2018), owing to the increased 
population and reliance on food that does not meet best practice regulations (Bhat and Vasanthi 
2003). 
Human exposure to mycotoxins occurs through the ingestion of contaminated grain products and 
animal products containing secondary metabolites (Zain 2011). Inhalation and dermal contact 
have also been described in an occupational setting, from airborne dust, spores and hyphae 
fragments (Pal, Gizaw et al. 2015, Viegas, Viegas et al. 2018). The extent of exposure can be 
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described as acute or chronic effects, that are associated with disease progression (Coulombe Jr 
1993). Acute toxicity can be described as a rapid exposure to a toxin over a short period, with a 
distinct toxic response, while chronic toxicity is due to exposure to toxin over a longer period, in 
smaller doses (Bennett and Klich 2003). Exposure to mycotoxins leads to the occurrence of 
diseases known as mycotoxicosis, expressed as blood toxicity, food poisoning and cancer (Zain, 
Awaad et al. 2014, Ahmed Adam, Tabana et al. 2017).  
2.1.3 Biological effects of mycotoxins 
Mycotoxins are ranked higher than synthetic contaminants, plant toxins, food additives and 
pesticide residues, as  the most important chronic dietary risk factors (Bennett and Klich 2003). 
A general mechanism is not associated to mycotoxins due to their diverse chemical structures and 
extensive variety of biological effects (Kiessling 1986). The biological effects of mycotoxins are 
characterized by their ability to alter cellular processes, which range from DNA and protein 
biosynthesis, to metabolism (Kiessling 1986). The interaction of mycotoxins with the DNA 
template, and disturbed transcription and translation, interfere with protein synthesis, thus exhibit 
aberrant enzyme activity and regulation (Kiessling 1986).  
Among the mycotoxins, aflatoxin B1 (AFB1) is the most carcinogenic, it can penetrate the cell 
membrane and bind to DNA to attain stability forming DNA adducts (Woo, Egner et al. 2011). 
The liposolubility of AFB1 facilitates its absorption in to the cell, where it is metabolized by 
cytochrome P450 in the liver, to a highly unstable epoxide that binds to DNA or a protein 
molecule (Ahmed Adam, Tabana et al. 2017). The binding of the metabolite to DNA causes GC 
to TA transversion mutations, directly affecting the p53 tumour suppressor gene and subsequently 
cell cycle (Baertschi, Raney et al. 1988). Therefore it comes as no surprise that AFB1 is the most 
potent hepatocarcinogen in mammals and listed as a Group 1 carcinogen (Muhammad, Sun et al. 
2017). In the intestine, exposure to AFB1 caused intestinal lesions via the disruption of intestinal 
barrier, cell proliferation, cell apoptosis, and immune system (Liew and Mohd-Redzwan 2018). 
Ochratoxin A is a nephrotoxin with potent liver toxicity, teratogenicity, carcinogenic and immune 
suppressant in humans and animals (Kuiper-Goodman and Scott 1989). It has been shown to 
inhibit mitochondrial adenosine triphosphate (ATP) production, stimulate lipid peroxidation 
(Arya, Shergill et al. 2005), lead to the formation of DNA adducts, apoptosis and oxidative stress 
(Kőszegi and Poór 2016). 
Trichothecene mycotoxins have inhibitory effects on eukaryotic cells where they inhibit protein, 
DNA and RNA synthesis, mitochondrial function and cell membranes (Rocha, Ansari et al. 2005). 
2.2 The Fumonisins 
Fumonisins are produced by the Fusarium verticilliodies species which commonly infect maize 
and associated agricultural products, throughout  the world  (Stockmann-Juvala and Savolainen 
2008). This strain was first isolated in 1970 from a batch of mouldy maize, and implicated in 
leukoencephalomalacia in horses in South Africa (Marasas 2001). Maize and maize-based 
products (Figure 2.1) are most frequently contaminated by this fungus, however garlic bulbs, 
onion powder, nuts and soybeans are also contaminated with Fumonisin (Seefelder, Gossmann et 
al. 2002, Boonzaaijer, Van Osenbruggen et al. 2008, Liu, Liu et al. 2008, Aoyama, Nakajima et 
al. 2010). Fumonisins are sub-divided into four groups: Serial A, B, C and P (Dutton 1996). 
Fumonisin B1 is considered the most toxic of the groups (Marasas 1996), and represents between 
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70% to 80% of the total Fumonisin content in naturally contaminated foods and feed (Krska, 
Welzig et al. 2007). 
 
 
Figure 2.1: Fusarium contaminated maize (A) and wheat (B)(Dutton 1996, Bergstrom 2014). 
2.3 Fumonisin B1 
2.3.1 Chemical Structure  
Fumonisins are polar water-soluble compounds with long chain structures (Figure 2.2). The 
structure of FB1 is representative of a diester of propane-1,2,3-tricarboxylic acid and 2-amino-
12,16-dimethyl-14,15-dihydrooxyecosane, in which the hydroxyl (OH) groups on carbon 14 and 
15 are esterified to form tricarboxylic acid (TCA). As opposed to the cyclic nature of other 
mycotoxins, FB1 has a polyketide-derived backbone which facilitates the attachment of TCA, 
methyl, OH and amino groups (Figure 2.2) (Stockmann-Juvala and Savolainen 2008). 
The primary amine group in FB1 shares a significant resemblance to sphingolipid precursors, 
sphinganine and sphingosine. This affords FB1 the ability to disrupt sphingolipid metabolism. It 
has been shown that the acetylation of the amino group in FB1 inhibits its toxicity and disruption 
of sphingolipid metabolism (Stockmann-Juvala and Savolainen 2008). 
 








2.3.3.1 Toxicity in animals 
Fumonisin B1 has been reported to induce many animal diseases, due to the contamination of their 
feed.  It is regarded as the most hazardous mycotoxin causing animal ill-health and associated 
economic loss. The liver and kidney are the foremost targets of FB1 in most animal species.  The 
pathogenic effects include equine leukoencephalomalacia (Marasas, Naude et al. 1976), porcine 
pulmonary oedema syndrome (Kriek, Kellerman et al. 1981), hepatic tumour in rats (Gelderblom 
and Snyman 1991), acute and fatal nephrotoxicity and hepatotoxicity in lambs (Edrington, 
Kamps-Holtzapple et al. 1995). Toxic responses including decreased body weight gain, increased 
mortality, size reduction of bursa of Fabricius, thymus and spleen, myocardial degeneration, 
myocardial haemorrhage, alterations in homeostatic mechanisms and necrosis of hepatocytes, 
have all been observed in chickens, ducklings and turkeys (Lumsangkul, Chiang et al. 2019). 
2.3.3.2 Toxicity in Humans 
Humans are continually exposed to low doses of FB1, the daily tolerable intake is 2µg (WHO, 
2002), however the consumption can range from 12 to 140µg/person per day, with peaks at 
2500µg/person where maize forms part of dietary staples (WHO 2012). 
The consumption of FB1 contaminated maize by pregnant woman, was associated with the onset 
of neuronal tube defects (NTD) in offspring. Folate deficiency is a causative factor of NTD. The 
alterations in sphingolipid content of cell membranes as a result of FB1, disrupts the folate receptor 
and prevents the uptake of folate, leading to NTD (Sadler, Merrill et al. 2002). 
Human epidemiological studies in South Africa, Italy and China highlighted the relationship 
between oesophageal cancer and the intake of maize grains contaminated with FB1 (Liew and 
Mohd-Redzwan 2018). FB1-induced oxidative stress by increased reactive oxygen species (ROS) 
production and increased the antioxidant defences in osteoblastic cells (Khan, Phulukdaree et al. 
2018). The exposure of FB1 to HepG2 cells, induced oxidative stress and initiated the Nrf2-
regulated transcription of antioxidants (Arumugam, Pillay et al. 2019). 
The relation between FB1 and growth impairment in children has also been described (Kimanya, 
De Meulenaer et al. 2010, Shirima, Kimanya et al. 2015, Chen, Mitchell et al. 2018). Among 
children in Tanzania, the relationship between exposure to FB1 and the impact on growth was 
confirmed based on urinary biomarker levels of Fumonisin (Shirima, Kimanya et al. 2015). These 
growth impairments were attributed to the contamination of breast milk and cow’s milk, by 
Fumonisins (Polychronaki, West et al. 2007, Magoha, Kimanya et al. 2014). 
The consumption of FB1 is also associated to acute mycotoxicosis. In 27 villages in India, 
residents experienced an outbreak of diarrhoea and abdominal pain, after it was found that they 
consumed rain damaged mouldy maize and sorghum, which exhibited higher levels of FB1 





2.3.2 Mechanism of action 
2.3.2.1 Canonical mechanism 
Due to the structural resemblance of FB1 to sphingoid bases, the main action of the toxin is to 
disrupt sphingolipid metabolism (Heidtmann-Bemvenuti, Mendes et al. 2011). Eukaryotic cells 
are abundant in sphingolipids as they are major constituents of membranes, lipoproteins, and lipid 
rich structures. Sphingolipids maintain the structure of membranes, like cholesterol, and modulate 
receptor activity (Merrill Jr, Schmeiz et al. 1997). Thus it comes as no surprise that FB1 induces 
lipid peroxidation that alters the cell membrane, causing apoptotic cell death (Soriano, Gonzalez 
et al. 2005).  
The synthesis of sphingolipids occurs de novo within the endoplasmic reticulum. The enzyme 
serine palmitoyl transferase initiates sphingolipid synthesis via the catalysation of the 
condensation of serine and palmitoyl coenzyme A (palmitoyl CoA) to yield 3-ketosphinganine. 
This is then reduced to sphinganine in a nicotinamide adenine dinucleotide phosphate (NADPH)- 
dependent manner (Futerman and Riezman 2005). There are two fates of sphinganine; it can 
undergo phosphorylation to form sphinganine-1-phosphate or, acylation by ceramide synthase to 
form dihydroceramide. Another major function of ceramide synthase is for the recycling of 
sphingosine to ceramide via the sphingolipid degradation pathway (Šegvić and Pepeljnjak 2001). 
Due to the structural similarity of the aminopentol backbone between FB1 and sphingoid bases, 
ceramide synthase identifies FB1 as a substrate, thus there exists competition for the binding site 
in ceramide synthase. The enzyme is also inhibited by the tricarboxylic group of FB1, which 
obstructs the fatty acyl-CoA binding site on ceramide synthase (Wang, Norred et al. 1991). These 
combined effects on the enzyme, impede ceramide biosynthesis, disrupting the formation of 
essential sphingolipids. This leads to an accumulation of sphingosine and sphinganine and 
disturbed sphingosine recirculation (Figure 2.3). As concentrations of sphingoid bases increases, 











Figure 2.3: The resultant disruption of sphingolipid metabolism by FB1 (prepared by author). 
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2.3.2.2 Emerging mechanisms 
Fumonisin B1 also has the potential to inhibit protein synthesis and DNA synthesis, at higher 
concentrations. Fumonisin B1 decreases the activities of DNA methyltransferases and induces 
global DNA hypomethylation and histone demethylation, resulting in chromatin instability 
(Chuturgoon, Phulukdaree et al. 2014). 
Recently it was discovered that FB1 induced oxidative DNA damage, via the downregulation of 
expression, of tumour suppressor phosphatase and tensin homolog (PTEN) via miR-30c 
(Arumugam, Ghazi et al. 2020). PTEN is a key maintenance factor of genomic stability and DNA 
repair, thus responds to DNA damage by inhibiting the phosphoinositide 3-kinase/protein kinase 
B signalling cascade, preventing the inhibitory phosphorylation of checkpoint kinase 1 (Ming and 
He 2012). This prevents the repair of FB1 induced oxidative DNA lesions, which contributes to 
the cytotoxicity and carcinogenicity (Arumugam, Ghazi et al. 2020). 
2.4 The Liver 
2.4.1 Liver functions and structure 
The liver is a vital organ in the body that is responsible for a multitude of functions that enable 
metabolism, immunity, digestion, detoxification, vitamin storage and excretion (Kalra and Tuma 
2018). The liver is the storage centre for fat-soluble vitamins and facilitates cholesterol 
homeostasis. The metabolic and synthetic functions of the liver include carbohydrate, lipid, and 
protein metabolism (Campbell 2006). It also manages the synthesis of plasma proteins, mainly 
albumin, binding globulins, protein C, protein S and clotting factors of the intrinsic and extrinsic 
pathways (Miller, Bly et al. 1951).  
The excretion of exogeneous compounds such as xenobiotics and endogenous substances like 
bilirubin take place from the liver. But before they can be excreted, exogenous chemicals are 
metabolized. There are two types of enzymatic manipulations that occur to an exogenous 
compound, depending on its structure, that are classified under the general headings of Phase I 
and Phase II reactions (Grant 1991). Phase I reactions include oxidation, reduction, and hydrolysis 
by multiple enzymes classes, to either introduce or expose functional groups (often hydroxyl 
groups) to facilitate its excretion by increasing its hydrophobicity. Phase II reactions are 
conjugative or synthetic, with the aim of adding water -soluble side groups to increase the 
excretability of the chemical. These biotransformation’s are aimed for detoxification however, 
inactive compounds (prodrugs) can be consequently converted to active metabolites, by attaining 
altered structures, that can influence its pharmacological specificity (Grant 1991). Consequently, 
the liver is exposed to significant concentrations of chemicals, that can result in liver dysfunction, 
cellular injury, and organ failure. 
 It also secrets bile, a fluid that aids in the absorption and digestion of lipids (Kalra and Tuma 
2018). The immunological ability of the liver is achieved by hepatic macrophages known as 
Kupffer cells (Fenton 2001).  
The liver comprises several cell types of different embryological origin and specified function. It 
includes hepatocytes, biliary epithelial cells, stellate cells, Kupfer cells and liver sinusoidal 
endothelial cells (Trefts, Gannon et al. 2017). Hepatocytes make up most of the liver volume and 
are highly metabolic in nature (Figure 2.4). They are rich in smooth and rough endoplasmic 
reticulum, essential for xenobiotic metabolism and protein synthesis respectively (Gu and 
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Manautou 2012). The liver is also rich in mitochondria forming an integrated hub of carbohydrate, 
lipid, and protein metabolism, required for hepatocyte survival and death. 
 
 
Figure 2.4: Structure of the liver (Premkumar 2004). 
2.4.2 Use of the HepG2 cell line  
The primary culture of hepatocytes is a profound model for investigating the effect of substances 
on human liver cells (Snopov, Teryukova et al. 2017). The hepatocellular carcinoma cell line is 
of particular use in liver toxicity studies and drug-induced mitochondrial toxicity, due to their 
similar function and metabolic profile to intact hepatocytes (Kamalian, Chadwick et al. 2015, 
Ramirez, Strigun et al. 2018). These are nontumorigenic cells with high proliferative rates and 
epithelial-like morphology that accomplish differentiated hepatic function (Donato, Tolosa et al. 
2015). These cells can adapt their phenotype, in response to nutrient availability. This is attributed 
to HepG2 cells being the most characterized cells in terms of signalling pathways and 
transcriptional response (Lai, Forde et al. 2018). It is for these reasons that the HepG2 cell line is 
employed in this study, to determine the effect of FB1 on cholesterol homeostasis in galactose 
supplemented media. 
2.5 Galactose media  
Cancer cells differ from normal cells with respect to their energy metabolism as they take up 
glucose and glutamine excessively for aerobic glycolysis, while still retaining the function of 
oxidative phosphorylation (OXPHOS) (Zheng 2012). Glycolysis is less energy efficient, yielding 
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less ATP than OXPHOS, cancer cells rely on this due to the speed of ATP generation, which is 
suited to the energy demands of cancer cells for rapid proliferation (Zheng 2012). This 
phenomenon is described as the Crabtree effect, that relies on glucose-induced inhibition of cell 
respiration and thus on OXPHOS (Orlicka-Płocka, Gurda-Wozna et al. 2020). The proven method 
of circumventing this phenomenon is to replace glucose with galactose in the culture media. 
Several studies have demonstrated the efficacy of this approach to activate mitochondria and force 
cells to rely on OXPHOS for ATP production, as demonstrated in Figure 2.5 (Aguer, Gambarotta 













Figure 2.5: Galactose induces OXPHOS in cancer cells to produce ATP efficiently (prepared by 
author). 
2.6 Mechanisms and regulation of cholesterol homeostasis 
The liver is the leading metabolic organ that maintains the body’s cholesterol and bile acid 
homeostasis. These molecules are steroid molecules that exert essential roles for biological 
functions. Cholesterol is an essential component of cell membranes and plays an important role 
in the make-up of lipid bilayers, as it is necessary for membrane biogenesis and cell proliferation 
(Maxfield and van Meer 2010, Silvente-Poirot and Poirot 2012). It is also a precursor for the 
biosynthesis of steroid hormones, lipid-soluble vitamins, and bile acids (Russell 1999, Russell 
2003).  
The cellular levels of cholesterol are determined by the interaction between de novo biosynthesis, 
uptake, export and storage (Figure 2.6) (Luo, Yang et al. 2020). Cholesterol synthesis begins from 
Acetyl-CoA and involves intense action of more than 20 enzymes localized in the membrane of 
the endoplasmic reticulum. Dietary sources also account for cholesterol and are absorbed by 
Niemann-Pick type C1-like 1 (NPC1L1) protein in enterocytes in the intestine (Altmann, Davis 
et al. 2004). The dietary cholesterol is then released as chylomicrons, from which cholesterol can 
be taken up by the liver. The liver is then responsible for the delivery of endogenously synthesized 
and exogenous cholesterol to the bloodstream as very-low-density lipoproteins (VLDLs). Once 
processed in the bloodstream, VLDLs give rise to low-density lipoprotein/s (LDL/s), which are 
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taken up by cells via LDL receptor-mediated endocytosis (Brown and Goldstein 2009). Vascular 
and non-vascular mechanism transport cholesterol to various organelles with in the cell, to satisfy 
its specific functions (Maxfield and van Meer 2010). 
Cholesterol biosynthesis is energetically expensive as it demands Acetyl-CoA, ATP, oxygen and 
reducing intermediates (NADPH/NADH). The cholesterol biosynthetic pathway is mediated by 
SREBP2 as it is a transcriptional regulator of the rate-limiting enzymes,: 3-hydroxy-3-methyl-
glutaryl coenzyme A reductase (HMGCR) and squalene monooxygenase (Maxfield and van Meer 
2010). However, cholesterol flux remains the focus of this study as reviewed below. 
2.6.1 Regulation of cholesterol uptake 
Apart from biosynthesis, cholesterol homeostasis is maintained by the diet via cholesterol uptake 
from the blood. Two mechanisms of cholesterol uptake are explained, the first being cholesterol 
uptake from the intestinal lumen via the NPC1L1 and secondly LDLR mediated uptake of LDL 
cholesterol from the blood, both  through a clathrin-dependent pathway (Luo, Yang et al. 2020). 
Within polarized cells, like hepatocytes, LDLR is found on the basolateral membrane to facilitate 
its function, while NPC1L1 is on the opposite side to acquire unesterified cholesterol from the 
intestine lumen. 
2.6.1.1 LDLR-mediated LDL endocytosis 
The LDL-receptor is principle for the uptake of cholesterol by peripheral cells. It is cell surface 
glyco-protein with five structural and functionally detailed domains (Jeon and Blacklow 2005). 
LDLR contains an N-terminal apolipoprotein B (apoB) and apolipoprotein E (apoE) binding 
domain, an epidermal growth factor (EGF) domain, a six-bladed β-propeller and a third EGF-like 
repeat, an O-linked oligosaccharide-rich domain, a transmembrane domain and a short C-terminal 
tail (Jeon and Blacklow 2005). 
SREBP2 is a transcriptional factor of LDLR, and once synthesized the 120kDa precursor 
undergoes glycosylation to form a mature 160kDa protein located on the plasma membrane 
(Lopez, Socarrás et al. 2007, Wijers, Kuivenhoven et al. 2015). 
Circulating cholesterol is captured by surface LDLR via the extracellular ligand binding domain, 
forming the LDLR-LDL complex, and recruits endocytic adaptors to enable the incorporation of 
LDL into clathrin-coated vesicles. This leads to LDLR pinching off the plasma membrane and 
entering the endocytic pathway (Luo, Yang et al. 2020). Within the acidic environment of the 
endosome, LDLR is subjected to conformational changes to facilitate the release of LDL 
(Rudenko, Henry et al. 2002). LDLR then has the ability to return to the cell surface via the 
endosomal recycling complex for additional endocytosis, or it can interact with PCSK9 which 
directs LDLR to lysosomal degradation (Zhang, Ma et al. 2016, Luo, Yang et al. 2020). At the 
plasma membrane, LDLR can also be targeted for lysosomal degradation in a process that is 
regulated by the E3 ligase, namely the inducible degrader of the LDL receptor (IDOL) (Zelcer, 
Hong et al. 2009). 
The process involved in IDOL-induced degradation of LDLR follows a complex ubiquitination 
of LDLR allowing for lysosomal degradation (Luo, Yang et al. 2020). Several factors are 
implicated in regulating this event, however the most prominent is LXR. LXRs bind to the IDOL 
promotor and upregulate its expression, and in accordance, the activation of the LXR-IDOL 
13 
 
system using synthetic LXR agonists, decreased LDLR levels and reduced LDL uptake (Zelcer, 
Hong et al. 2009, Hong, Marshall et al. 2014).  
2.6.1.2 PCSK9-induced degradation of LDLR and its regulation 
PCSK9 belongs to the secretory serine protease family as one of nine proprotein convertases. 
Structurally it contains a prodomain, a catalytic domain and a specialized C-terminal domain that 
is rich in both Cysteine and Histidine residues (Seidah and Prat 2012). The prodomain of a newly 
synthesized precursor, serves as the N-terminal domain that is self-cleaved in the endoplasmic 
reticulum, and non-covalently binds to the rest of the protein, consequently blocking protease 
activity. PCSK9 is modified by glycosylation, phosphorylation and sulfation, until it is finally 
released into the extracellular environment where it binds to LDLR and other proteins (Lagace 
2014).  
A portion of the catalytic domain on PCSK9 interacts with LDLR on the epidermal growth factor 
(EGF) repeat, forming the PCSK9-LDLR complex (Kwon, Lagace et al. 2008). The complex is 
internalized via clathrin-coated pits and processed to endosomes, where the C-terminal of PCSK9 
is stimulated to interact with the ligand binding domain of LDLR, within an acidic environment 
(Tveten, Holla et al. 2012). The interaction increases the binding strength of the PCSK9-LDLR 
complex, preventing LDLR from achieving the recycling conformation, ultimately leading to 
lysosomal degradation (Zhang, Garuti et al. 2008, Lagace 2014). In HepG2 cells, PCSK9 can 
direct LDLR in the trans-Golgi towards lysosomal degradation (Li, Dong et al. 2009). 
SREBP2 upregulates PCSK9 along with other transcription factors and post-transcriptional 
regulators. 
2.6.2 Regulation of cholesterol efflux 
Excess cholesterol that cannot be catabolized is stored as cholesteryl esters in lipid droplets or 
disposed of out of the cell (Luo, Yang et al. 2020). The ATP-binding cassette (ABC) transporter 
superfamily are responsible for cholesterol efflux in a cell specific manner. ABC subfamily A 
member 1 (ABCA1) and ABC subfamily G (ABCG) mediate cholesterol efflux by macrophages, 
while ABCG5 and ABCG8 are present in hepatocytes and enterocytes (Luo, Yang et al. 2020). 
However, ABCA1 is expressed throughout the body and studies have highlighted the role of 
ABCA1 in hepatocytes (Bashore, Liu et al. 2019, Sasaki, Komatsu et al. 2019). 
2.6.2.1 ABCA1-mediated cholesterol efflux 
ABCA1 is a transport protein that has two tandem repeats of the membrane-spanning domains, 
each comprising of six transmembrane segments and a glycosylated extracellular domain (Luo, 
Yang et al. 2020). Lipid-free apolipoprotein A-I (apoA-I) is the primary acceptor for cholesterol 
efflux via ABCA1 (Rosenson, Brewer Jr et al. 2012). ABCA1 can flip or directly transport 
phospholipids across the lipid bilayer by lateral recruitment from the inner membrane (Qian, Zhao 
et al. 2017). ABCA1 mediates cholesterol efflux to apoA-I via three controversial mechanisms. 
The first suggestion is that ABCA1 can interact with apoA-I, when cholesterol and phospholipids 
are bound in the extracellular domain, allowing for transfer of the lipids to apoA-I (Nagata, 
Nakada et al. 2013, Ishigami, Ogasawara et al. 2018). The second view is that ABCA1 induces 
the formation of an activated microdomain, by promoting phospholipid transport, that protrudes 
from the cell surface to facilitate apoA-1 binding (Phillips 2018). ABCA1 the unfolds the N-
terminus, allowing apoA-1 to be inserted into the membrane, initiating micro-solubilization of the 
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lipid bilayer, allowing for the efflux of cholesterol and phospholipids. The third view is that 
ABCA1 and apoA-1 undergo clathrin-dependent endocytosis from the cell surface to lysosomes, 
allowing apoA-1 to receive LDL cholesterol through ABCA1 directly from NPC intracellular 
cholesterol transported 2 (NPC2) (Boadu, Nelson et al. 2012). 
Cholesterol export is regulated at the transcriptional level by LXRs and RXR (Costet, Luo et al. 
2000). LXR targets the ABCA1 and ABCG1 genes to promote the efflux of cellular cholesterol 
in an attempt to maintain sterol homeostasis (Repa, Turley et al. 2000). 
Figure 2.6: Major pathways of cholesterol metabolism and flux (Luo, Yang et al. 2020). 
2.7 The role of cholesterol in cancer development 
Irrespective of their critical functions in the body, excesses of cholesterol and bile acids lead to 
human diseases in the form of cardiovascular disease, hepatobiliary disease and liver cancer 
(Kemper, Choi et al. 2013). In addition the disturbance of the homeostatic state is known to be 
associated with cardiovascular disease attributed to dietary and lifestyle habits (Hu, La Vecchia 
et al. 2012).  
The role of cholesterol in carcinogenesis has increased, with clinical evidence that suggest that 
changes in cholesterol metabolism is involved in the onset of cancer (Silvente-Poirot and Poirot 
2012). Cholesterol can activate oncogenic signalling, due to it being a cell membrane component 
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can close relation to membrane receptors (Ding, Zhang et al. 2019). It has been reported that 
cholesterol can activate the oncogenic Hedgehog signalling pathway, a well-known cancer 
associated signalling pathway, by binding the smoothened receptor (Huang, Nedelcu et al. 2016). 
The activation of this pathway is associated with cell differentiation, cell proliferation and tumour 
formation (Hooper and Scott 2005). 
In conjunction to the cell membrane, cholesterol also has functions in the cytoplasm.  It was 
shown that lysosomal cholesterol could lead to the activation of mTORC1, which is also 
associated with increased cell proliferation, invasion and metastasis (Kim, Cook et al. 2017). 
Apart from being a key component for membrane integrity, cholesterol is also an important 
component of lipid rafts. Lipid rafts are small specialized lipid domains within the cell membrane, 
whose structure and function are reliant on the composition of cholesterol and phospholipids 
(Yan, Qu et al. 2014). Lipid rafts facilitate signal transduction for oncogenic signalling pathways, 
and alterations in cholesterol level impair the structural integrity of lipid rafts, leading to the 
activation or inhibition of death receptor proteins, protein kinases and calcium channels (George 
and Wu 2012). 
Changes in cholesterol metabolism during cancer development occur during cholesterol synthesis 
and cholesterol flux. Therefore, it is imperative that these processes are tightly regulated, to evade 
disease states. 
2.8 The role of SIRT1 in lipid regulation and cancer  
There are seven sirtuin proteins in mammals (SIRT1-7) that are ubiquitously expressed and 
comprise of a common catalytic core domain but also have specialized features in their respective 
cellular localizations, enzymatic functions and target proteins (Kemper, Choi et al. 2013). The 
sirtuins are of particular interest due to their diverse roles in various physiological ad pathological 
events including life-span extension, neurodegeneration, age-related disorders, obesity, heart 










Figure 2.7: SIRT1 NAD-dependent deacetylase activity (Revollo and Li 2013). 
SIRT1 is a NAD-dependent deacetylase (Figure 2.7) that plays extensive roles in cellular 
metabolism and stress response by regulating the activity of transcription factors and cofactors by 
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protein deacetylation (Ponugoti, Kim et al. 2010). SIRT1 is primarily localized in the nucleus and 
has a role in genomic stability, telomere maintenance and cell survival (Chen, Zhang et al. 2011). 
It is responsible for the removal acetyl groups from the ε-amino group of lysine residues of histone 
and non-histone protein targets thus altering their function (Haberland, Montgomery et al. 2009). 
2.8.1 SIRT1 lipid and cholesterol regulation 
Studies have shown that SIRT1 inhibits hepatic lipogenesis by deacetylating SREBP-1c, a known 
key lipogenic activator, during a fasted state (Ponugoti, Kim et al. 2010). SREBPs are 
transcription factors that bind to DNA, specifically involved in the regulation of cellular lipid and 
cholesterol levels (Brown and Goldstein 1997). SREBPs exist as three isoforms (SREBP-1c, -1a 
and 2) encoded by two genes (Horton, Bashmakov et al. 1998). SREBP-2 is synthesized by a 
separate gene, while SREBP-1c and -1a are synthesized by the same gene. SREBP-1c is 
abundantly expressed in adult liver, and in a fed state, binds to and activates its lipogenic target 
genes, such as fatty acids synthase, Acetyl CoA carboxylase, stearyl CoA desaturase and 
interestingly its own gene SREBP-1c, resulting in increased fatty acid synthesis (Repa, Liang et 
al. 2000). Biochemical proteomic analysis and mechanistic study highlighted that SREBP-1c is 
acetylated by p300 and deacetylated by SIRT1 at Lys-289 and Lys-309 resulting in downregulated 
SREBP-1c transcriptional activity by promoting ubiquitination and proteasomal degradation 
(Ponugoti, Kim et al. 2010, Walker, Yang et al. 2010). 
SIRT1 also plays a critical role in cholesterol metabolism by deacetylating, and inducing the 
activity of oxysterol receptors, LXRs (LXRα and LXRβ) (Kemper, Choi et al. 2013). Therefore 
SIRT1-mediated deacetylation of LXRs can lead to reverse cholesterol transport and hepatic 
lipogenesis (Kemper, Choi et al. 2013). Both LXR and SREBP-1c contribute to the transcriptional 
activation of the SREBP-1c gene (Yoshikawa, Shimano et al. 2001), thus termination of SREBP-
1c activity by SIRT1-mediated deacetylation may allow SIRT1 to exhibit beneficial effects on 
cholesterol metabolism (Kemper, Choi et al. 2013). 
2.8.2 The role of SIRT1 in liver cancer 
The role of SIRT1 in cancers remains controversial since they could act as either a tumour 
suppressor or tumour promoter dependent on a host of factors: the cellular context, its targets in 
signalling pathways and specific cancers (Lin and Fang 2013). 
SIRT1 is regarded as a tumour promoter due to its increased expression in cancer cell types and 
its role in the inactivation of tumour suppressor proteins and DNA damage repair (Choi, Bae et 
al. 2011). The same group found that the expression of SIRT1 was significantly higher in 
hepatocellular carcinoma (HCC) tissues, as compared to non-tumour tissues. Another study 
showed that SIRT1 is overexpressed in HCC and that it plays an oncogenic role via the 
enhancement of cell proliferation and resistance to chemotherapy (Chen, Jeng et al. 2012). 
2.9 The impact of FB1 on cholesterol  
Previously it was shown that FB1 can translocate from a water environment to a lipid phase 
containing cholesterol and/or bile salts, and FB1 demonstrated the ability to bind to cholesterol 
(Mahfoud, Maresca et al. 2002). This provides reason for the interest in the toxin and its effect on 
humans. As such, the effect of FB1 on cholesterol homeostasis has been poorly addressed. 
Therefore, this study aims to determine the effect of FB1 on cholesterol homeostasis, by 
examining the major proteins central to cholesterol flux. This will offer an understanding of the 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Materials 
Fumonisin B1 (FB1), isolated from Fusarium moniliforme, was obtained from Sigma-Aldrich (St 
Louis, MO, USA). The human hepatocellular carcinoma (HepG2) cell line was attained from 
Highveld Biologicals (Johannesburg, South Africa). The cell culture reagents and supplements 
were purchased from Lonza BioWhittaker (Basel, Switzerland). Western Blot reagents were 
purchased from Bio-Rad (Hercules, CA, USA) and anti-bodies were procured from Abcam 
(Cambridge, UK). All other reagents were obtained from Merck (Darmstadt, Germany) unless 
otherwise stated. 
3.2 Cell culture 
The liver is considered the centre of metabolism and it is responsible for detoxification of harmful 
xenobiotics. FB1 has been reported to cause hepatocarcinogenicity and disrupt lipid metabolism. 
The liver plays a central role in lipid metabolism. Collectively these reasons warrant the use of 
the HepG2 cell line in this study. 
3.2.1 Cell culture conditions 
The HepG2 cells were cultured in monolayer (106 cells per 25cm3 culture flask) using complete 
culture media [CCM: Eagle’s Essential Minimal Media (EMEM) supplemented with: 10% foetal 
calf serum, 1% penstrepfungizone and 1% L-glutamine] at 37°C in a humidified incubator. After 
every 48 hours, cells were washed with 0.1M phosphate buffered saline (PBS) and reconstituted 
with CCM (5ml). 
For treatments HepG2 cells were exposed to galactose media [Gibco Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with: 10mM galactose, 6mM L-glutamine, 5mM 4-2-
hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 10% foetal calf serum, 1mM sodium 
pyruvate, and 1% penstrepfungizone]. 
3.2.2 Preparation of Fumonisin B1 
A 5mM stock of FB1 was prepared by dissolving 2mg of FB1 in 0.1M PBS (554.2µl). 
3.2.3 Cell preparation for assays 
HepG2 cells were allowed to reach 80% confluency in 25cm3 flasks before treatments. Cells were 
washed with 0.1M PBS and culture media was replaced with galactose media. After 1hr the 
galactose media was removed, and cells were washed, to allow for the phenotypic change to 
induce oxidative phosphorylation. A concentration of 25µM was obtained from cell viability 
assays and used in all subsequent assays supplemented with galactose media. Two controls were 
prepared, an untreated control containing CCM and galactose media, respectively. 
After the 6hr incubation, cells were detached using trypsinization and gentle agitation; the Trypan 
Blue exclusion method of cell counting was utilized to determine cell viability and cell number 
as per assay requirements. The galactose control was employed for statistical comparison against 
FB1 treatment; all experiments were performed as three independent experiments and in triplicate 
for each assay. 
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Maize contains approximately 72% starch, 10% protein, and 4% fat, thus supplying an energy 
density of 365 Kcal/100g. It can be processed into a variety of food products and has a  low 
production cost, thus along with the high consumption of maize flour, particularly where 
micronutrient deficiencies are common public health concerns, make this food a part of the staple 
diet (Ranum, Peña‐Rosas et al. 2014). In African countries such as Zambia, Malawi, Zimbabwe, 
South Africa and Kenya, many people eat maize meal twice or three times a day (FIhlani 2019). 
Therefore, a 6hr treatment was decided upon to resemble a single exposure profile, and satisfies 
the half-life of the toxin (Martinez-Larranaga, Anadon et al. 1999). 
3.3 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
3.3.1 Principle 
The MTT assay is a colorimetric test commonly used to determine the cytotoxicity of a compound 
at variable concentrations, but also a method to measure cell viability. The assay directly measures 
mitochondrial activity as the enzyme mitochondrial dehydrogenase converts the MTT salt into an 
insoluble formazan salt, illustrated by a yellow to purple colour change (Figure. 3.1). It is 
postulated that viable cells have constant mitochondrial activity, allowing the assay to accurately 
distinguish cell viability. 
Figure 3.1: The structures and conversion of MTT salt to Formazan via mitochondrial reductase 
as a measure of cell viability (prepared by author). 
The concentration of solubilized formazan is measured by a spectrophotometer at 570nm with a 
reference wavelength of 690nm. A decrease viability is indicative of growth inhibition, while 
toxin sensitivity is expressed at a concentration that indicates 50% growth inhibition (IC50) (van 
Meerloo, Kaspers et al. 2011). 
3.3.2 Protocol 
The cell viability of HepG2 cells in FB1, supplemented with galactose media, was determined 
using the MTT assay. Approximately 20,000 cells/well (triplicate) were seeded overnight in a 96-
well microtitre plate (37°C, 5% CO2). Then cells were washed with 0.1M PBS and supplemented 
with galactose media (200µl) only for 1hr. Thereafter, cells were washed again with PBS and 
treated with variable concentrations of FB1 (0-500µM - 200µl) for 6hrs. Control cells contained 
CCM only (200µl). Following the incubation, treatments were removed, and cells were washed 
with PBS. The cells were then incubated with MTT salt (20µl; 5mg/ml in 0.1M PBS) and CCM 
(100µl) for 4hrs. The MTT solution was removed and replaced with dimethyl sulphoxide (DMSO) 
(100µl per well) and incubated for 1hr. The optical density was measured using a 
spectrophotometer (BioTek uQuant, Winooski, VT, USA) at a wavelength of 570nm with a 
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reference wavelength of 690nm. The percentage cell viability was calculated by standardizing 
control cells to 100% and then comparing this relative to FB1 treated cells. Results were expressed 
as log concentration versus percentage cell viability using GraphPad Prism v5.0 software. 
3.4 ATP luciferase assay 
3.4.1 Principle 
The major energy molecule of the cell is adenosine triphosphate (ATP), its production is vital for 
cellular process.  To satisfy the demand for energy, the mitochondria produces ATP via the 
electron transport chain (ETC) which is coupled to OXPHOS in addition to substrate level 
phosphorylation. Cancer cells depend on glycolysis to generate ATP rather than OXPHOS, even 
when oxygen and functional mitochondria are available. Suppressing glycolysis by galactose 
supplementation, upregulates mitochondrial function and subsequently forces cells to rely on 
OXPHOS to obtain ATP, which is more energy efficient (Zheng 2012, Shiratori, Furuichi et al. 
2019).  
The CellTire Glo™ (Promega) assay was used to determine ATP concentration. The assay relies 
on bioluminescence to measure ATP levels in cells, based on the luciferase reaction. Luciferin is 
mono-oxygenated to oxy-luciferin in the presence of Mg2+, O2 and ATP. This reaction produces 
energy in the form of luminescence, which is directly proportional to the concentration of ATP in 
the cells (Figure 3.2). The light can be measured with a luminometer. 
Figure 3.2: The structures and chemical conversion of luciferin to oxyluciferin involved in the 
CellTire Glo™ assay to quantify cellular ATP concentration (prepared by author). 
3.4.2 Protocol 
The CellTire Glo™ assay was used to determine the amount of ATP in FB1 treated HepG2 cells, 
supplemented with galactose. Approximately 20,000 cells were aliquoted into a white opaque 
microtitre plate (triplicate), followed by 25µl CellTire Glo™ reagent (Promega, Madison, USA) 
and then incubated the in dark (30min, RT), to allows the reaction to propagate. The luminescent 
signal was measured by employing a Modulus™ microplate luminometer (Turner Biosystems, 
Sunnyvale, USA). The relative luminescent signal was used to determine intracellular ATP 
concentration and then expressed as relative light units (RLU). 
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3.5 Lactate dehydrogenase (LDH) assay 
3.5.1 Principle 
Cell membrane integrity can be determined by measuring the activity of cytoplasmic enzymes, 
released by damaged cells. The cytoplasmic enzyme, LDH, is present in all cells and is released 
into cell culture supernatant, when cell membrane integrity is compromised. The amount of LDH 
activity correlates to the degree of membrane damage.  
The LDH enzyme activity is measured via a two-step enzymatic test. The first step involves the 
reduction of NAD+ to NADH/H+ by the conversion of lactate to pyruvate, catalysed by LDH. The 
second step, the diaphorase enzyme transfers H/H+ for the NADH/H+ species, to the tetrazolium 
salt INT, forming a formazan product (Figure 3.3). The amount of formazan product can be 
measured spectrophotometrically and correlated to the activity of LDH. 
Figure 3.3: Reactions of the LDH membrane integrity assay (prepared by author). 
3.5.2 Protocol 
To measure cell membrane integrity, the extracellular LDH detection kit (Roche) was employed. 
Supernatant (100µl) was aliquoted into a 96-well microtitre plate (triplicate). Thereafter, substrate 
mixture (100µl) containing catalyst and dye solution (diaphorase/ NAD+ and INT/sodium lactate) 
was added to the samples and incubated (20min, RT). The optical density of the formazan product 
was measured using a spectrophotometer (Bio-Tek uQuant, Winooski, VT, USA) at 500nm. The 
results were expressed as mean optical density. 
3.6 Protein Isolation, quantification, and standardization 
3.6.1 Principle 
Protein isolation was mandatory for western blotting. Protein isolation was carried out on ice to 
prevent protein degradation, using both mechanical (cell scraper) and chemical lysis (Cytobuster) 
techniques. The crude protein was quantified and then standardized to ascertain whether enough 
protein was available, to carry out the assays, and to make distinguishable comparisons between 
samples (Huang, Long et al. 2010).  
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The bicinchoninic acid (BCA) assay was employed to determine protein concentration. The 
reaction is dependent on two chemical reactions, under alkaline conditions. Firstly, the biuret 
reaction involves the reduction of cupric ions (Cu2+) into cuprous ions (Cu+) via the formation of 
peptide bonds (Figure 3.4). The second reaction involves the chelation of Cu+ with two molecules 
of BCA, producing a powerful purple chromophore, which absorbs light at a maximum of 562nm. 
The intensity of the signal produced is directly proportional to the concentration of the protein; it 
is proportional to the reduction of Cu2+. 
The concentrations of the protein samples are determined using a standard curve. Briefly a set of 
bovine serum albumin (BSA) standards are prepared, and their absorbances are used to plot the 









Figure 3.4: A summary of the BCA assay for protein quantification. Reaction A illustrates the 
reduction of Cu2+, to form free Cu+, while reaction B illustrates the chelation of two BCA 
molecules to Cu+ (prepared by author). 
3.6.2 Protocol 
Crude protein was extracted using Cytobuster™ (200µl) (Novagen, USA) which was 
supplemented with protease and phosphatase inhibitors (Roche, 05892791001 and 04906837001, 
respectively) to maintain the integrity of the protein samples. 
The cells were incubated on ice with Cytobuster™ for 10min, followed by mechanical lysing and 
finally decanted into 2ml micro-centrifuge tubes. Cell lysates were centrifuged (13,000xg, 10min, 
4°C) to yield crude protein, which was then quantified using the BCA assay. 
A set of BSA standards (0 – 1 mg/ml) were prepared, and 25µl of the samples (in duplicate) and 
the standards (in triplicate) were dispensed into a 96-well microtiter plate.  The BCA working 
solution (196µl BCA: 4µl CuSO4 per well) was also dispensed into each well. The plate was then 
incubated in the dark for 30min at 37°C. The optical density of the samples and standards was 
determined using a spectrophotometer (BioTek uQuant, Winooski, VT, USA). A standard curve 
was constructed and employed to determine the protein concentrations of the samples. Once 




3.7 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western 
blotting 
3.7.1 Principle 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting 
are advantageous techniques, applied for the expression profiles of target proteins. Briefly, it 
involves the separation of proteins on the basis of molecular size, followed by the transfer of these 
proteins onto a membrane, and lastly detection of a target protein via immunoblotting (Kurien 
and Scofield 2006). 
3.7.1.1 Sample Preparation 
Prior to separation via SDS-PAGE, standardized proteins are boiled in Laemmli buffer. The 
components of the buffer are key factors that allow for optimum electrophoresis (Table 3.1). 
Boiling the samples provides a high temperature for the denaturation of proteins and subsequent 
breakage of disulphide bonds (Mahmood and Yang 2012).  
Table 3.1: The components of Laemmli buffer and their functions. 
Component  Function 
Glycerol Contributes to the density of the sample, allowing the 
samples to settle more efficiently at the bottom of the 
wells of the gel. 
Sodium dodecyl sulphate (SDS) Causes the proteins to denature, acquire a homogenous 
negative charge and linearization. 
Β-mercaptoethanol Breaks down disulphide bonds by reduction, allowing for 
protein unfolding and linearity. 
Bromophenol Blue Allows for the tracking of samples during electrophoresis. 
Tris-HCl Used as a buffer and maintains pH of the proteins during 
electrophoresis.  
 
3.7.1.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Following sample preparation, samples were separated based on their respective molecular 
weights using SDS-PAGE. In an electric field, particles with a uniform charge are drawn towards 
an electrode with the opposing charge. By denaturing the protein samples using Laemmli buffer, 
the charge of the proteins is unified (negatively charged), therefore the samples are drawn towards 
the positive electrode. The Laemmli buffer ensures that the proteins adopt their primary state, 
which allows for separation to occur based on their respective molecular weights only, and not 
their shape or charge (Mahmood and Yang 2012). 
For the proteins to separate based on their size, they migrate through polyacrylamide gels. The 
gels are polymers formed by acrylamide and N, N’-methylene bis-acrylamide which together, 
form cross-links, that impede the migration of the proteins. Low percentage gels have fewer cross-
links, thus have larger pores for larger molecules to pass through. Equally, high percentage gels 
have much smaller pores on accord of more cross-linking. 
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Two types of gels are employed in SDS-PAGE: resolving and stacking gels (Figure 3.5). The 
resolving gel, which has a higher content of polyacrylamide as compared to the stacking gel, has 
smaller pores, due to more cross-links. Allowing for better separation of proteins, based on their 
respective sizes. The stacking gel has a lower polyacrylamide content, thus has larger pores, 
allowing for poor separation of proteins. This ensured that the proteins all began separating at the 
same point, for a fair and equal separation (Mahmood and Yang 2012).  
The rate of migration is therefore dependent on the gel percentage, size of the protein, shape, and 
charge. Larger proteins remain closer to the origin, while smaller proteins migrate through the 
crosslinks and can be found lower on the gel, the same can be said in terms of the shape of the 
proteins. Molecular markers are employed to enable determination of the respective sizes of target 













Figure 3.5: A simplified illustration of the migration of proteins, based on size, through the two 
gel layers (prepared by author). 
3.7.1.3 Western blotting 
Western blotting allows for the transfer of separated proteins from the polyacrylamide gel, to a 
nitrocellulose membrane. The nitrocellulose provides a solid support for the proteins. The 
polyacrylamide gel and membrane are sandwiched between two fibre pads and plate electrodes 
(Figure 3.6). The sandwich allows for uniform transfer of separated proteins. The gel and 
membrane sandwich are exposed to an electric field perpendicularly, driving the negatively 








Figure 3.6: The configuration of the polyacrylamide gel and nitrocellulose membrane between 
fibre pads, sandwich, for western blotting (prepared by author). 
Once proteins are transferred, target proteins are detected using specific antibodies. Before 
antibodies are used, the membrane was incubated with BSA or non-fat dry milk (NFDM). This is 
a blocking step that minimizes non-specific binding of antibody to the membrane, reducing any 
background (Gavini and Parameshwaran 2020). Antibodies are species specific. Primary antibody 
binds to the target protein on the nitrocellulose membrane, and the secondary antibody attaches 
to the primary antibody-protein complex. The secondary antibody is conjugated to the enzyme 
horse radish peroxidase (HRP), which produces a signal when the primary and secondary 
antibodies bind (Figure 3.7). A chemiluminescent detection reagent (luminol) which is oxidized 
by HRP, is applied to enhance the signal (Kurien and Scofield 2006). The intensity of the emanated 
light signal is directly proportional to the expression of the target protein (Gavini and 
Parameshwaran 2020). 
Figure 3.7: The signal emitted after successful immunoblotting (prepared by author). 
3.7.1.4 Detection 
The emanated light signals are detected using a high-power camera-based imaging system. By 
comparing the protein bands to that of the molecular weight marker, the target protein can be 
distinguished between other bands. To normalize the target protein expression, a housekeeping 
protein is employed, allowing for accurate protein level determination. The housekeeping protein, 
usually β-actin or  glyceraldehyde 3-phosphate dehydrogenase (GAPDH), is constitutively 
expressed and is used to correct for loading error and protein concentration variation (Gavini and 




3.7.2.1 Sample Preparation 
Standardized proteins were boiled in Laemmli buffer [dH2O, 0.5M Tris-HCl (pH6.8), glycerol, 
10% SDS, β-mercaptoethanol, and 1% bromophenol blue] for 5min in a water bath at 100°C. 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Polyacrylamide gels for SDS-PAGE were prepared using the Mini-PROTEAN Tetra Cell casting 
frame (Bio-Rad). A 12% resolving gel [dH2O, 30% Bis-acrylamide, Tris (1.5M, pH8.8), 10% 
SDS, 80% glycerol, 10% Ammonium persulphate (APS), and Tetramethyl ethylenediamine 
(TEMED)] was prepared and allowed to set for 2min. Then, a 4% stacking gel [dH2O, 30% Bis-
acrylamide, Tris (0.5M, pH6.8), 10% SDS, 80%, APS, and TEMED] was set on top of the 
resolving gel. For the formation of wells, a 1cm plastic comb was positioned between the glass 
plates, and the gel was allowed to set (40min). 
Thereafter, the gel cassettes were moved into the electrode assembly and positioned inside the 
electrode tank (Mini-PROTEAN Tetra Cell System, Bio-Rad). Before the combs were removed, 
running buffer (25mM Tris, 192mM glycine and 0,1% SDS) was poured into the tank. Protein 
samples (25µl) and the molecular weight marker (5µl) (Precision Plus Protein All Blue Standards, 
catalogue no. #161-0373, Bio-Rad) were then loaded into wells. The electrophoresis tank was 
topped with running buffer and electrophoresed [150 volts (V), 1hr) using a Bio-Rad compact 
power supply. The assembly was kept on ice. 
3.7.2.2 Western blotting 
Nitrocellulose membranes, fibre pads and electrophoresed gels were equilibrated in transfer 
buffer (25mM Tris, 191.8mM glycine and 20% methanol), for 10mins. Thereafter, the gel 
sandwich was prepared (Figure 3.6), and placed between the two electrodes of the transfer 
equipment. The separated proteins were then electro-transferred onto the nitrocellulose membrane 
using the Bio-Rad Trans-Blot Turbo Transfer System (30min, 20V). 
Once transferred, the membranes were blocked with blocking solution. Either 5% BSA or 5% 
NFDM in Tween 20-Tris buffered saline (TTBS: 150mM NaCl, 3mM KCl, 25mM Tris, 0.05% 
Tween 20, dH2O, pH7.5), was used, and gently shaken [1hr, Room temperature (RT)]. 
Membranes were immunoblotted with primary antibody (Table 3.2), overnight (4°C). After 
incubation, the membranes were equilibrated to RT, the primary antibody was discarded, and 
membranes were washed using TTBS (5 times, 10min). Thereafter, membranes were probed with 
HRP-conjugated secondary antibody (Table 3.2) while gently shaken (2hr, RT). Membranes were 
washed with TTBS (5 times, 10min) and target protein bands were visualized and captured using 
the iBright Western Blot Imaging Systems (ThermoFisher). 
Once proteins were detected, membranes were quenched with 5% H2O2 for 30min, and incubated 
in 5% BSA (1hr, RT). Membranes were washed three times in TTBS and probed with HRP-
conjugated anti-β-actin. Protein expressions were determined using the iBright Analysis Software 
(ThermoFisher) and expressed as relative band density (RBD). Target protein expression was 




Table 3.2: Target protein antibodies and dilutions used in western blotting 
 
3.8 Real Time Quantitative Polymerase Chain Reaction 
3.8.1 Principle 
The conventional polymerase chain reaction (PCR) is a simple tool used for the rapid 
amplification of specific gene sequences, from template bands. Thermostable Taq polymerase 
drives the synthesis of complementary DNA (cDNA) strands by the addition of deoxynucleoside 
triphosphates (dNTPs) to the 3’end of oligonucleoside primers. These primers are complementary 
to the DNA sequence that flank the target gene (Pestana, Belak et al. 2010). For a successful PCR 
to occur, the following components are essential: 
• DNA template – comprises the target sequence. 
• Forward and Reverse primers – allows for the binding to the 3’ends of the forward and 
reverse stands of the target sequence. 
• Taq polymerase – serves as a catalyst for the synthesis of new strands of DNA, that are 
complementary to the target sequence. 
• Deoxynuceloside triphosphates (dNTPs) – provide the building blocks utilized in the 
synthesis of new strands of DNA. 
• MgCl2 – a stabilizing agent for DNA and ensures optimal functioning of Taq 
polymerase. 
• Buffer system – maintains ideal pH for the PCR reaction to occur. 
The PCR reaction is completed in a thermocycler where it undergoes continuous cycling of three 
steps at distinct temperatures. These three steps make up one cycle of a PCR reaction (Figure 3.8). 
The three steps include:  
1. Denaturation – initiated at 95°C allowing the H bonds between double stranded (ds) 
DNA to break, yielding single stranded (ss) DNA. 
2. Annealing – the temperature is lowered to 55°C and the primers hybridize to 
complementary sequences, flanking the 3’ end of the target sequence.  






Rabbit Anti-LXR alpha 1:1000 in 5% BSA ab106464 (Abcam) 
Mouse Anti-ABCA1 1:1000 in 5% BSA ab66217 (Abcam) 
Rabbit Anti-SREBP1 1:1000 in 5% BSA ab28481 (Abcam) 
Rabbit Anti-LDLR 1:1000 in 5% BSA ab52818 (Abcam) 
Rabbit Anti-SIRT1 1:1000 in 5% BSA ab32441 (Abcam) 
Rabbit Anti-PCSK9 1:1000 in 5% BSA ab125251 (Abcam) 
Secondary 
Antibody 
Goat Anti-Rabbit IgG 
HRP 
1:10,000 #7074S (Cell Signalling 
Technology) 
 Rabbit Anti-Mouse IgG 
HRP 
1:10,000 ab6728 (Abcam) 
Housekeeping 
Antibody 
Anti-β-actin 1: 5000 in 5% BSA A3854 (Sigma Aldrich) 
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3. Extension – the temperature is the raised to 72°C, allowing optimal activity of Taq 
polymerase, which attaches dNTPs to the annealed primers, forming a copy of the DNA 
target gene. 
This cycle is repeated between 30 to 40 times to establish acceptable amplification (Arya, Shergill 
et al. 2005). 
Figure 3.8: The three steps of a single PCR cycle progressing up to DNA amplification (prepared 
by author). 
Unlike conventional PCR, quantitative PCR (qPCR) allows for the quantification of PCR 
amplicons generated during each cycle of the PCR process (Pestana, Belak et al. 2010). 
Amplicons can be detected using SYBR® Green 1, which is a DNA-intercalating dye. The dye 
fluoresces intensely when it binds to the minor groves of dsDNA. Therefore, the intensity of the 
emitted fluorescence is directly proportional to the amount of dsDNA present (Arya, Shergill et 
al. 2005).  
The expression of a housekeeping gene is analysed together with the gene of interest, in the 
samples. The amount of target DNA is thus reported relative to the amount of the housekeeping 
gene. Housekeeping genes are generally expressed at constant levels at all stages of development 
and their expression profiles remain relatively constant across samples (Arya, Shergill et al. 
2005). This allows for the normalization of target gene expression. Quantification of gene 
expression is determined, by comparing the gene expressions of the target and housekeeping 
genes, employing the Livak and Schmittgen method. The data is expressed in terms of fold change 




3.8.2.1 Ribonucleic acid isolation 
Treatments were removed and cells were incubated with 500µl of Qiazol (Qaigen, Hilden, 
Germany) and 500µl 0.1M PBS (5min, RT). The cells were then mechanically lysed and 
transferred into 1.5ml Eppendorf’s and stored overnight in Qiazol (-80°C). Thereafter, cells were 
thawed and 100µl of chloroform was added, then centrifuged (2,000xg, 15min, 4°C). Supernatant 
was collected and 250µl of isopropanol was added, samples were the stored overnight (-80°C). 
Samples were thawed and centrifuged (2,000xg, 20min, 4°C), the supernatants were discarded, 
and the resulting pellet was washed with 500µl ethanol (75%) and centrifuged (7,400xg, 15 min, 
4°C). The pellet was allowed to air dry, then resuspended in nuclease free water (15µl) and placed 
on ice. The amount of ribonucleic acid (RNA) was then quantified using the Nanodrop2000 
spectrophotometer (ThermoFisher Scientific), the A260/A280 ratios were used to evaluate RNA 
integrity. The RNA concentration of samples was then standardized to 1000ng/µl. 
3.8.2.2 Complementary deoxyribonucleic acid synthesis 
Complementary DNA was synthesized from crude RNA standards, using the iScript™ cDNA 
synthesis Kit (Bio-Rad, catalogue no. 107-8890) as per manufacturer’s instructions. A reaction 
mix was prepared for each sample (Table 3.3) 
Table 3.3: cDNA synthesis mixture for a single sample 
Reagent 1 x reaction volume (µl) 
5X iScript reaction mixture 2 
iScript reverse transcriptase 0.5 
Nuclease free water 1 
Standardized RNA template  2 
 
The samples were them incubated in a thermocycler (GeneAmp® PCR System 9700, Applied 
Biosciences, California, USA) for 40min (5min at 25°C, 30min at 42°C, and lastly 5min at 85°C). 
The cDNA was then stored (-20°C). 
3.8.2.3 Quantitative Polymerase Chain Reaction 
Gene expression of target genes was determined using the iQ™ SYBR® Green PCR kit and CFX 
Touch™ Real Time PCR Detection System (Bio-Rad, Hercules, CA, USA), as per manufacturer’s 
instructions. The mRNA expressions of ABCA1, LXR, LDLR and PCSK9 were investigated using 
forward and reverse primers (Table 3.5). The housekeeping gene, GAPDH was also determined 
as normalization factor. A reaction master mix was prepared to evaluate gene expressions in 







Table 3.4: Reaction mix for a single qPCR 
Reagent 1 x reaction volume (µl) 
SYBR® Green  5 
Forward primer 1 
Reverse primer 1 
Nuclease free water 2 
cDNA template 1 
  
The CFX Touch™ Real Time PCR Detection System was used to amplify the samples. As per 
qPCR conditions, the initial denaturation occurred at 95°C (4min), followed by 37 denaturation 
cycles [95°C, 15 seconds (sec)]; then annealing (40sec, temperatures as per Table 3.5) and 
extension (72°C, 30sec). The plate was then read. 
To determine changes in relative mRNA expression, the method described by Livak and 
Schmittgen was applied. The fold change in mRNA expression is expressed as 2-ΔΔCt. The 
expression of target genes was normalized against the expression of the housekeeping gene 
(GAPDH), which amplified simultaneously, under the same conditions. 




Primer Sequence (5’→ 3’) 





























3.9 Total cholesterol  
Total cholesterol in supernatants was determined by Quest Africa Diagnostics (a commercial 
pathology laboratory, Durban, South Africa). 
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3.10 Statistical analysis 
Microsoft Excel 2019 and GraphPad Prism version 5.0 (GraphPad Software Inc., California) were 
employed to perform statistical analysis. The unpaired t-test. All results were presented as the 


























CHAPTER 4: RESULTS 
4.1 HepG2 cells express differential metabolic activity when exposed to FB1 in 
glucose and galactose media 
Cell viability and metabolic activity of cells can be estimated quantitatively via exposure to 
tetrazolium salts. This provides viability and metabolic distinction, between glucose and galactose 
metabolism in FB1 treated HepG2 cells.  
The MTT assay displays contrasting relations to cell viability and media type, in FB1 treated cells. 
There is a general decrease in percent cell viability for the galactose media, while no significant 
change in percent cell viability is observed for the glucose medium (Figure 4.1). After 6 hrs, cell 
viability of the galactose medium was significantly decreased (25µM FB1), accounting for a 50% 
decrease in cell viability. Thus, treatment with FB1 supplemented by galactose was found to be 
acutely toxic with increased mycotoxin concentrations (0-250µM FB1), resulting in a decrease in 
cell viability and metabolic activity. 
 











4.2 HepG2 cells exhibit a decrease in metabolic activity however, without membrane 
disruption following FB1 exposure 
ATP is the energy currency of the cell, through determination of the level of ATP, the effect of 
FB1 on metabolic output can be uncovered. The ATP concentrations of FB1 treated cells was 
determined using the Cell Glo luminometry assay. In accordance with the decrease in viability 









Figure 4.2: A significant decrease in ATP concentration following 6hr treatment of FB1 on HepG2 
cells. **p<0.01. 
 
As cholesterol is a major component of the cell membrane, the effect of FB1 on membrane 
integrity was considered. Fumonisin B1 did not jeopardise membrane integrity, as there was no 















4.3 A minor change in cholesterol was demonstrated in HepG2 cells 
In order to survey the effect of FB1 on cholesterol flux, total cholesterol of cell supernatants was 
evaluated. Surprisingly, no significant change in total cholesterol was observed in FB1 treated 














Figure 4.4: Result of laboratory determination of total cholesterol reveal no significant change of 














4.4 FB1 increased SIRT1 expression to regulate the key lipogenic activator SREBP1 
The SIRT1 deacetylase has a critical role in cellular metabolism and stress responses by 
modulating the activity of transcription factors and cofactors by protein deacetylation. SIRT1 is 
an established regulator of lipid/cholesterol homeostasis and is known to deacetylate SREBP1 
and positively regulates LXR (Li, Zhang et al. 2007, Ponugoti, Kim et al. 2010). Accordingly, the 
gene and protein expressions of SIRT1 and SREBP were determined, the controllers of expression 
of fatty acid and triglyceride synthesis. 
The test concentration of FB1 increased SIRT1 gene (Figure 4.5A) and protein (Figure 4.5B) 
expression considerably in comparison to the control. Meanwhile a significant increase in 
SREBP1 gene (4.5C) expression was observed, but a significant decrease in protein expression 






Figure 4.5: In HepG2 cells FB1 increased the gene (A) and protein (B) expression of SIRT1 but 













4.5 FB1 increases expression of lipogenic transcription factor LXR and decreases the 
expression of PCSK9 
LXR is also a chief transcriptional regulator of cholesterol metabolism and homeostasis while, 
PCSK9 is a regulator of LDLR. Both LXR and PCSK9 are major regulatory proteins involved in 
cholesterol metabolism and homeostasis, that are regulated by SIRT1. Intrinsically the influence 
of FB1 on their expressions was explored. 
FB1 significantly increased the gene and protein expressions of LXR (4.6A and 4.6B), whereas a 







Figure 4.6: FB1 regulates cholesterol cellular flux in a PCSK9 dependent manner in HepG2 cells 
by decreasing its expression (A and B) irrespective of elevated expression of its transcriptional 













4.6 FB1 impacts cholesterol flux in HepG2 cells 
To ascertain the effect of FB1 on cholesterol flux, the expression profiles of cholesterol influx and 
efflux proteins were considered. FB1 increased gene and protein expression of LDLR significantly 
(Figure 4.7A and 4.7B) in comparison to the control.  A minor decrease in ABCA1 gene 
expression was observed for the FB1 treatment (Figure 4.7C), while a significant increase in 








Figure 4.7: In HepG2 cells FB1 stimulates lipid uptake (B) but also promotes cholesterol efflux 














CHAPTER  5: DISCUSSION 
Mycotoxins have attracted worldwide attention owing to their negative impacts on human health 
and economic losses. However, the downsides of economic calamity do not exceed the harm to 
human life. The physiological consequence of FB1 toxicity is attributed to dysregulated lipid 
metabolism and lipidomic profiles which can disrupt membrane integrity and lipid raft formation 
(Merrill Jr, Schmeiz et al. 1997, Riedel, Abel et al. 2016, Burger, Abel et al. 2018). It is known 
that FB1 inhibits ceramide synthase with a consequential accumulation of sphinganine, 
sphingosine and their 1-phosphate derivatives, while depleting complex sphingolipids (Merrill Jr, 
Schmeiz et al. 1997). In addition, in vivo and in vitro studies in rat liver and primary hepatocyte 
models show that FB1 increased circulating cholesterol levels (Riedel, Abel et al. 2016, Burger, 
Abel et al. 2018). In the present study the effect of FB1 on SIRT1 is established and evidence is 
provided to suggest that FB1 disrupts cholesterol homeostasis in a cholesterol flux dependent 
manner, in the HepG2 liver cell line. 
The liver is the central metabolic organ and is an important modulator of cholesterol homeostasis 
(Takeyama, Uehara et al. 2017). The HepG2 cell line is the ideal model for investigating the effect 
of xenobiotics on the human liver and have the ability to adapt their phenotype in response to 
nutrient availability (Snopov, Teryukova et al. 2017, Lai, Forde et al. 2018).  The MTT assay 
illustrates that HepG2 cells exposed to FB1 supplemented with galactose, is more cytotoxic as 
compared to HepG2 cells exposed to FB1 in glucose media, after 6hrs. These findings advocate 
that there is a stark contrast in HepG2 metabolic response to FB1, between glucose and galactose 
media. Thus, the decrease in metabolic activity as highlighted by the decrease in cell viability, 
supports the phenotypic adaptation of HepG2 cells.  
An IC50 value of 25µM for FB1 (6hrs) was obtained for HepG2 cells supplemented with galactose 
media, from the MTT assay. This IC50 is much lower than the 200µM reported previously 
following a 24hr treatment (Chuturgoon, Phulukdaree et al. 2014, Arumugam, Ghazi et al. 2020). 
This difference may be due to the different treatment times, and the growth medium (glucose vs 
galactose). It was also noted that glucose offered protection against FB1 toxicity in swine and rats 
(Liu, Lu et al. 2001, Fernandez-Surumay, Osweiler et al. 2004). As such, the galactose media was 
used in subsequent assays, as this forced the cells to adopt aerobic metabolism. This adjustment 
in metabolism mimics the metabolic profile of normal cellular metabolism (Aguer, Gambarotta 
et al. 2011). 
In addition to the decreased cell viability (Figure 4.1), the metabolic output of HepG2 cells 
declined significantly, as illustrated by a decreased cellular ATP output (Figure 4.2). This result 
is predictable, as with decreased cell viability, a decrease in ATP would be expected. In this study 
HepG2 cells were stimulated to divert from glycolysis, to rely on OXPHOS to provide energy, by 
replacing glucose media with galactose (Aguer, Gambarotta et al. 2011, Shiratori, Furuichi et al. 
2019, Orlicka-Płocka, Gurda-Wozna et al. 2020). Glycolysis is less energy efficient, yielding less 
energy than OXPHOS. However, this alone does not explain the decrease in cellular ATP level. 
It is therefore speculated, that the decrease in ATP level is due to FB1. In rat primary astrocytes 
and human neuroblastoma, FB1 was found to inhibit mitochondrial complex I, resulting in a 
decreased rate of mitochondrial and cellular respiration (Domijan and Abramov 2011). Previously 
it was suggested that glucose deprivation and mitochondrial complex I inhibition, synergize and 
induce cancer cell death (Palorini, Simonetto et al. 2013). Therefore, it is presumed that the 
decrease in ATP level, is due to the effect of FB1. 
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Cell death is a result of activation of intrinsic cell death programs or passive disruption of 
membrane integrity, by external factors (Zhang, Chen et al. 2018). The LDH leakage assay is 
particularly sensitive to chemicals that directly damage cellular membranes (Ivanova and Uhlig 
2008). The data herein indicate that membrane integrity was not compromised after the exposure 
to FB1 for 6hrs as evidenced by no significant release of LDH (Figure 4.3). These contrasting data 
of decreased cell viability, decreased ATP output and no disruption of membrane integrity, 
suggests that FB1- induced loss of membrane integrity is dependent on factors such as cell/tissue 
type, concentration, and duration of exposure. 
The role of cholesterol in cancer development has increased, clinical evidence suggests that 
changes in cholesterol metabolism is associated with cancer (Silvente-Poirot and Poirot 2012), 
and that cholesterol can activate oncogenic signalling (Ding, Zhang et al. 2019). Changes in 
cholesterol metabolism during cancer, occur during cholesterol synthesis and cholesterol flux. 
Previously it was reported that FB1 decreased the level of free cholesterol within primary rat 
hepatocytes (Gelderblom, Smuts et al. 1996), as a result of a decreased level of sphingomyelin in 
cell membranes, which has an influence on cholesterol synthesis and metabolism (Gupta and 
Rudney 1991) .The determination of total cholesterol in cell supernatants suggest that FB1, has 
no significant change in cholesterol flux, evidenced by no significant change in cholesterol level 
(Figure 4.4). However, a decrease in cholesterol levels were observed, and can be attributed to 
minor changes in cholesterol flux proteins, over a short FB1 exposure. Another reason may be 
that the laboratory method for total cholesterol determination, is specialized for blood samples 
and not optimized for cell supernatants. 
Various studies have highlighted the role of SIRT1 as a tumour promoter, with evidence of 
increased expression in hepatocellular carcinoma (Chen, Jeng et al. 2012, Lin and Fang 2013). In 
addition, SIRT1 has a major role in cholesterol regulation, due to its effect on SREBPs and LXRs 
(Ponugoti, Kim et al. 2010, Kemper, Choi et al. 2013). The data presented in this study highlights 
the possible role of SIRT1 regulatory activity on SREBP-1c, LXR and PCSK9 in FB1 treated 
HepG2 cells, supplemented by galactose media, for 6hrs.  
The expression of SIRT1 is dependent on the levels of ATP, with ATP negatively regulating  
SIRT1 activity (Kang, Oka et al. 2017). QPCR and Western blot analysis of SIRT1 exhibit 
significant increases in both gene and protein expressions (Figure 4.5A and 4.5B) with a decrease 
in ATP levels (Figure 4.2). This is the first observation on the effect of FB1 on SIRT1, despite the 
influence of ATP. Concurrently, differential gene and protein expression of SREBP-1c was noted 
(Figure 4.5C and 4.5D), in FB1 treated HepG2 cells. The decrease in SREBP-1c protein 
expression is explained by the deacetylase activity of SIRT1. The deacetylation of SREBP-1c by 
SIRT1 at Lys-289 and Lys-309 (Ponugoti, Kim et al. 2010), inhibits SREBP-1c activity by 
decreasing its stability and its association to its lipogenic target gene promoters. However, this 
observation does not coincide with the observed increased gene expression. This is attributed to 
the vast regulation of SREBP-1c at the transcriptional level (Eberlé, Hegarty et al. 2004). The 
expression of SREBP-1c can be up-regulated by insulin signalling due to carbohydrate uptake 
(Azzout-Marniche, BÉCARD et al. 2000), or via LXR-mediated induction, which can manage 
fatty acid and cholesterol homeostasis (Repa, Liang et al. 2000, Schultz, Tu et al. 2000) or by 
autoactivation (Amemiya-Kudo, Shimano et al. 2000). Therefore, the increase in SREBP-1c gene 
expression can be explained further, by activity of LXR. 
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It is known that LXRs play a critical role in cholesterol metabolism, and are targeted by SIRT1 
for deacetylation, promoting the activity of LXR (Feige and Auwerx 2007). Both LXR and 
SREBP-1c contribute to the transcriptional activation of the SREBP-1c gene (Yoshikawa, 
Shimano et al. 2001), therefore the significant increase in LXR expressions (Figure 4.6A and 
4.6B), can account for the increase in SREBP-1c  despite the low protein expression of SREBP-
1c. LXR can act as a cholesterol sensor, and induce SREBP-1c for the generation of fatty acids 
for the formation of cholesterol esters (Tontonoz and Mangelsdorf 2003). 
LXR and PSCK9 further regulate the expression of cholesterol flux proteins. The transcription of 
LDLR is regulated by a pathway involving LXR, which maintains cholesterol homeostasis 
through upregulation of the IDOL, consequently activating the ubiquitination and degradation of 
LDLR (Zelcer, Hong et al. 2009). Despite the increase in LXR expression, there is no decrease in 
LDLR gene and protein expression (Figure 4.7A and 4.7B). This suggest that the inhibitory effect 
of LXR on the LDLR pathway, through the transcriptional induction of IDOL, is not active. 
However, this study does not consider the effect of IDOL on LDLR. Thus, the attention was 
turned to PCSK9, the induced degrader of LDLR (Li, Dong et al. 2009). PCSK9 is a protein 
involved in the post-translational degradation of LDLR, thereby restricting its recycling to the 
cell membrane (Athavale, Chouhan et al. 2018). This is supported by the data, which highlights 
that gene and protein expression of PCSK9 had decreased significantly, in HepG2 cells treated 
with FB1 (Figure 4.6C and 4.6D). 
These contrasting data suggests that the deacetylation of LXR by SIRT1, prevents the degradation 
of LDLR via the IDOL pathway, and suppresses the activity of PCSK9. This suggestion is 
supported by the evidence that SIRT1 suppresses the PCSK9 gene, reducing PSCK9 secretion, 
resulting in increased LDLR expression (Miranda, van Tits et al. 2014). This is further supported 
by the increased SIRT1 expression. Taken together, these findings suggest that FB1 influences 
cholesterol up-take in a SIRT1 dependent manner. 
To further evaluate the effect of FB1 on cholesterol flux, the expression of ABCA1, the transport 
protein responsible for cholesterol efflux was determined (Bashore, Liu et al. 2019). The ABCA1 
gene is targeted by LXR at the transcriptional level, to promote cholesterol efflux (Repa, Turley 
et al. 2000). The gene expression of ABCA1 exhibits a slight decrease, while the protein 
expression is significantly increased (Figure 4.7C and 4.7D). Although the protein expression of 
ABCA1 is significantly increased, there total cholesterol of the FB1 treatment is lower than the 
control. It is speculated that the protein is not specialized for cholesterol efflux in the HepG2 cell 
line, but rather macrophages. The ABC transporter superfamily are responsible for cholesterol 
efflux in a cell specific manner, with ABCA1 mediated cholesterol efflux in macrophages and 
ABCG5 in hepatocytes (Luo, Yang et al. 2020). Thus, FB1 increases the expression of ABCA1 
cholesterol efflux protein, but has no apparent effect on cholesterol efflux in HepG2 cells. 
The cancer promoting properties of FB1  (Gelderblom, Abel et al. 2001) have recently been linked 
to changes in lipid raft composition and altered cholesterol profiles (Burger, Abel et al. 2018). 
Our data provides the molecular basis for carcinogenic events observed in FB1 toxicity by 
dysregulating the circuitry involved in cholesterol metabolism, particularly with respect to lipid 
influx and cholesterol efflux from liver cells. 
A summary of the effect of FB1 on cholesterol flux and its possible role in carcinogenicity in 




Figure 5.1: Summarised account of events. FB1 in galactose media inhibits the ETC, resulting in 
decreased ATP leading to increased SIRT1 activity. This subsequently results in decreased 
SREBP-1c and PCSK9 expression, but increased LXR expression. As a result, the expression of 
LDLR in increased, leading to cholesterol influx, promoting carcinogenicity (prepared by author). 
5.1 Limitations of study 
This study employed an in vitro liver model to assess the effect on FB1 exposure, on cholesterol 
homeostasis. In vitro studies do allow for more detailed analysis compared to in vivo studies 
however, a short coming of the employed model is that the cells are removed from their natural 
environment, thus eliminating interactions and mechanisms that would otherwise be available. To 
overcome this shortfall, the use of an in vivo mouse model in addition to a primary hepatocyte 
cell model may provide a better understanding of how cells will respond to FB1, with respect to 
cholesterol homeostasis. 
Due to the COVID-19 pandemic, a total cholesterol kit and ABCG5 protein antibodies could not 









CHAPTER 6: CONCLUSIONS 
6.1 Conclusions 
With the large availability of food, a substantial part of life is spent in the postprandial state, thus 
allowing dietary toxins to direct cellular phenotypes and induce a state of metabolic toxicity. For 
the first time, the relationship between SIRT1 and FB1 is characterized. In the context of this 
study, SIRT1 is induced by FB1 in galactose supplemented HepG2 cells, leading to disturbed 
cholesterol flux. We further show that these effects are dependent on the LXR transcription factor 
and PCSK9. These results reiterate the toxicological relevance of FB1 in the dysregulation of 
cholesterol metabolism and underlines the potential of this toxin in promoting changes in 
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Appendix 1: Raw data for MTT assay (6hrs) 














0 0,000 1,26 0,42 100,00 100,00 
5 0,699 1,19 0,40 94,72 94,27 
10 1,000 1,23 0,32 97,74 76,61 
25 1,398 1,28 0,26 101,88 61,81 
50 1,699 1,23 0,20 98,17 47,10 
100 2,000 1,14 0,19 91,03 44,71 
250 2,398 1,23 0,17 98,04 40,73 
500 2,699 1,25 0,06 99,95 15,35 
 





























Figure 1: Standard curve of concentrations of bovine serum albumin versus optical density to 





































Figure 1: Complete western blot images in no particular order 
